MEDIWELCOME (02159) announced that on January 20, 2026, a subsidiary of the company and a potential seller signed a non-legally binding memorandum of understanding regarding the possible acquisition of 100% of the equity in Hong Kong Universal Yicheng Wisdom Technology Development Limited, together with its subsidiaries collectively referred to as the "Target Group". The Target Group primarily provides artificial intelligence technology to global pharmaceutical and medical device companies, revolutionizing medical research and physician specialist training through its AI-powered specialized disease vertical models, while also utilizing its core Web3 blockchain technology to ensure data authenticity, security, and traceability.